Neurocrine Biosciences (NBIX) EPS (Diluted) Growth (5y) (2015 - 2026)
Neurocrine Biosciences (NBIX) EPS (Diluted) Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.20% |
| Mar 31, 2026 | 42.40% |
| Dec 31, 2025 | -15.87% |
| Sep 30, 2025 | 39.65% |
| Jun 30, 2025 | 5.60% |
| Mar 31, 2025 | -27.53% |
| Dec 31, 2024 | 22.85% |
| Sep 30, 2024 | 17.32% |
| Jun 30, 2024 | 2.94% |
| Mar 31, 2024 | 18.87% |
| Dec 31, 2023 | 49.36% |
| Sep 30, 2023 | 9.40% |
| Jun 30, 2023 | 75.23% |
| Mar 31, 2023 | -11.05% |
| Dec 31, 2022 | 50.40% |
| Sep 30, 2022 | 42.47% |
| Jun 30, 2022 | 25.55% |
| Mar 31, 2022 | 16.62% |
| Dec 31, 2021 | 30.80% |
| Sep 30, 2021 | 20.15% |